Diagnostic Value of Circulating microRNAs for Lung Cancer: A Meta-Analysis
Authors:
- 1 May 2013
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 17 (5) , 359-366
Abstract
Background: Lung cancer is a leading cause of cancer mortality, and it shows a high incidence worldwide. Circulating microRNAs have been proposed as diagnostic indicators of lung cancer, but inconsistent results in the literature have prevented their widespread use in diagnosis. The present meta-analysis aimed to systematically evaluate the diagnostic accuracy of circulating microRNAs for lung cancer. Methods: Several research databases were searched systematically for studies of the accuracy of circulating microRNAs as diagnostic indicators of lung cancer. Results from different studies were pooled using random-effects models. Summary receiver operating characteristic (SROC) curves were used to assess the overall performance of microRNA-based assays. Results: Thirteen publications were included in the meta-analysis. The following summary estimates were obtained for the performance of circulating microRNAs in lung cancer diagnosis: sensitivity, 0.85 (95% confidence intervals [CI]: 0.83–0.87); specificity, 0.84 (95% CI: 0.81–0.86); positive likelihood ratio, 5.23 (95% CI: 3.75–7.29); negative likelihood ratio, 0.20 (95% CI: 0.14–0.27); and diagnostic odds ratio, 31.77 (95% CI: 16.98–59.42). The SROC curve indicated a maximum joint sensitivity and specificity of 0.85, with an area under the curve of 0.92. Conclusion: Circulating microRNAs show significant potential as diagnostic markers of lung cancer. The results of this meta-analysis justify larger, more rigorous studies to confirm such a diagnostic role.Keywords
This publication has 40 references indexed in Scilit:
- Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkersBMC Cancer, 2011
- A serum circulating miRNA diagnostic test to identify asymptomatic high‐risk individuals with early stage lung cancerEMBO Molecular Medicine, 2011
- Circulating miRNA signature for early diagnosis of lung cancerEMBO Molecular Medicine, 2011
- Circulating micro‐RNA expression profiles in early stage nonsmall cell lung cancerInternational Journal of Cancer, 2011
- Plasma microRNAs as potential biomarkers for non-small-cell lung cancerLaboratory Investigation, 2011
- miR-1254 and miR-574-5p: Serum-Based microRNA Biomarkers for Early-Stage Non-small Cell Lung CancerJournal of Thoracic Oncology, 2011
- MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancerProceedings of the National Academy of Sciences, 2011
- The National Lung Screening Trial: Overview and Study DesignRadiology, 2011
- Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseasesCell Research, 2008
- Computed Tomography Screening and Lung Cancer OutcomesJAMA, 2007